1. Home
  2. MRKR vs GRNQ Comparison

MRKR vs GRNQ Comparison

Compare MRKR & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • GRNQ
  • Stock Information
  • Founded
  • MRKR N/A
  • GRNQ 2013
  • Country
  • MRKR United States
  • GRNQ Malaysia
  • Employees
  • MRKR N/A
  • GRNQ N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • GRNQ EDP Services
  • Sector
  • MRKR Health Care
  • GRNQ Technology
  • Exchange
  • MRKR Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • MRKR 13.7M
  • GRNQ 12.7M
  • IPO Year
  • MRKR N/A
  • GRNQ 2018
  • Fundamental
  • Price
  • MRKR $0.89
  • GRNQ $1.38
  • Analyst Decision
  • MRKR Strong Buy
  • GRNQ
  • Analyst Count
  • MRKR 3
  • GRNQ 0
  • Target Price
  • MRKR $13.17
  • GRNQ N/A
  • AVG Volume (30 Days)
  • MRKR 2.6M
  • GRNQ 18.0K
  • Earning Date
  • MRKR 08-14-2025
  • GRNQ 08-12-2025
  • Dividend Yield
  • MRKR N/A
  • GRNQ N/A
  • EPS Growth
  • MRKR N/A
  • GRNQ N/A
  • EPS
  • MRKR N/A
  • GRNQ N/A
  • Revenue
  • MRKR $5,388,071.00
  • GRNQ $3,256,679.00
  • Revenue This Year
  • MRKR N/A
  • GRNQ N/A
  • Revenue Next Year
  • MRKR $15.82
  • GRNQ N/A
  • P/E Ratio
  • MRKR N/A
  • GRNQ N/A
  • Revenue Growth
  • MRKR 44.55
  • GRNQ N/A
  • 52 Week Low
  • MRKR $0.81
  • GRNQ $0.80
  • 52 Week High
  • MRKR $5.95
  • GRNQ $2.50
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 30.85
  • GRNQ 41.40
  • Support Level
  • MRKR $0.81
  • GRNQ $1.43
  • Resistance Level
  • MRKR $0.98
  • GRNQ $1.56
  • Average True Range (ATR)
  • MRKR 0.10
  • GRNQ 0.10
  • MACD
  • MRKR -0.03
  • GRNQ 0.01
  • Stochastic Oscillator
  • MRKR 14.39
  • GRNQ 31.11

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

Share on Social Networks: